The eyes in diabetes and diabetes through the eyes

被引:9
作者
Harman-Boehm, Ilana [1 ,2 ]
Sosna, Tomas [3 ]
Lund-Andersen, Henrik [4 ,5 ]
Poita, Massimo [6 ]
机构
[1] Soroka Univ, Med Ctr, Dept Internal Med C, Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Diabet Unit, Beer Sheva, Israel
[3] IKEM, Cent Diabetol, Prague, Czech Republic
[4] Univ Dept Herlev Hosp, Copenhagen, Denmark
[5] Steno Diabet Ctr, Copenhagen, Denmark
[6] Univ Turin, Turin, Italy
关键词
diabetic retinopathy; protein kinase C; renin-angiotensin system; microvascular complications; AGE; polyols;
D O I
10.1016/j.diabres.2007.09.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatens sight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation of protein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight. (c) 2007 Published by Elsevier Ireland Ltd.
引用
收藏
页码:S51 / S58
页数:8
相关论文
共 49 条
[11]   Diabetic retinopathy [J].
Fong, DS ;
Aiello, LP ;
Ferris, FL ;
Klein, R .
DIABETES CARE, 2004, 27 (10) :2540-2553
[12]  
FUNATSU H, 1992, JPN J OPHTHALMOL, V36, P356
[13]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[14]   Lipid-lowering drug atorvastastin as an adjunct in the management of diabetic macular edema [J].
Gupta, A ;
Gupta, V ;
Thapar, S ;
Bhansali, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (04) :675-682
[15]   Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy [J].
Hall, Anthony P. .
TOXICOLOGIC PATHOLOGY, 2006, 34 (06) :763-775
[16]   Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein [J].
Hara, T ;
Inami, M ;
Hara, T .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 126 (04) :560-564
[17]   UNDIAGNOSED NIDDM - CLINICAL AND PUBLIC-HEALTH ISSUES [J].
HARRIS, MI .
DIABETES CARE, 1993, 16 (04) :642-652
[18]   Surgery for diabetic retinopathy [J].
Helbig, Horst .
OPHTHALMOLOGICA, 2007, 221 (02) :103-111
[19]   Progression of retinopathy in insulin-treated type 2 diabetic patients [J].
Henricsson, M ;
Berntorp, K ;
Fernlund, P ;
Sundkvist, G .
DIABETES CARE, 2002, 25 (02) :381-385
[20]   Severe hypoglycemia and smoking in a long-term type 1 diabetic population - Wisconsin Epidemiologic Study of Diabetic Retinopathy [J].
Hirai, Flavio E. ;
Moss, Scot E. ;
Klein, Barbara E. K. ;
Klein, Ronald .
DIABETES CARE, 2007, 30 (06) :1437-1441